| CAS NO: | 1450929-77-7 |
| 包装 | 价格(元) |
| 10mM (in 1mL DMSO) | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| Cas No. | 1450929-77-7 |
| 分子式 | C27H28N2O2 |
| 分子量 | 412.52 |
| 溶解度 | DMSO : 96.67 mg/mL (234.34 mM; Need ultrasonic) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | LHF-535 is an antiviral agent extracted from patent WO2013123215A2, Compound 38, has EC50s of<1 μM,<1 μM,<1 μM, and 1-10 μM for Lassa, Machupo, Junin, and VSVg virus, respectively[1]. LHF-535 is a small-molecule viral entry inhibitor that targets the arenavirus envelope glycoprotein (GP). LHF-535 exhibits potent antiviral activity against a broad array of hemorrhagic fever arenaviruses. LHF-535 inhibits Lassa GP-pseudotyped lentivirus with an IC50 of 0.1-0.3 nM[2]. LHF-535 (3, 10 or 30 mg/kg; orally; daily; 14 days) protectes mice from a lethal challenge with Tacaribe virus and dramatically reduces viral titers in plasma, spleen, and liver[2]. An increase in survival is also observed when the first dose of LHF-535 (10 mg/kg) is delayed by 1, 2, or 3 days after infection, demonstrating that LHF-535 is efficacious as a post-exposure therapeutic in mice[2]. [1]. Dongcheng Dai, et al. Antiviral drugs for treatment of arenavirus infection. WO2013123215A2. |
m.cnreagent.com